Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio

Harshad Devarbhavi; Arvind R Murali

doi:10.1016/j.jceh.2015.08.004

Back

Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio

Journal article

Open access

Peer reviewed

Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio

Harshad Devarbhavi and Arvind R Murali

Journal of clinical and experimental hepatology, Vol.5(4), pp.310-313

12/2015

DOI: 10.1016/j.jceh.2015.08.004

PMCID: PMC4723655

PMID: 26900272

Files and links (1)

url

https://doi.org/10.1016/j.jceh.2015.08.004View

Published (Version of record) Open Access

Abstract

Anticoagulation is the standard of care in patients with Budd-Chiari Syndrome (BCS). Ascites is a common symptom in patients with BCS. Often such patients require paracentesis while taking oral anticoagulation concurrently. It is unclear whether paracentesis leads to increased bleeding in such patients or whether anticoagulation has to be temporarily suspended. We describe our experience with paracentesis in patients with BCS taking oral anticoagulation. Our study subjects included consecutive patients with BCS with ascites on oral anticoagulation admitted between 2007 and 2011. The dose of oral anticoagulation was titrated to achieve international normalized ratio (INR) between 2 and 3. Routine hematological tests included Factor VIII (FVIII) levels. Paracentesis was undertaken without the prior administration of fresh frozen plasma and without the aid of ultrasonography. We looked for occurrences of bleeding at the puncture site or hemoperitoneum during and after the procedure. Thirty-two of the 60 patients with BCS patients taking oral anticoagulation concurrently developed ascites. Thirty among 32 patients required paracentesis on one or more occasions. A total of 51 paracentesis procedures were performed (Median 1.6, Range 1-7). The mean INR was 3.1 (Range 1.4-7.9). No patient developed bleeding or hemoperitoneum. The mean FVIII measured was 138.8% of laboratory control and mean platelet level was 2.2 × 10(5)/ml. Ascitic paracentesis in patients with BCS on anticoagulation is safe without an increased risk of abdominal wall bleeding or hemoperitoneum. Normal or high FVIII and platelet levels likely mitigate against bleeding risks.

PT, Prothrombin Time

hepatic vein

paracentesis

anticoagulation

BCS, Budd Chiari Syndrome

INR, International Normalized Ratio

hemoperitoneum

INR

Details

Title: Subtitle: Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio
Creators: Harshad Devarbhavi - Department of Gastroenterology, St. John's Medical College Hospital, Bangalore, India
Arvind R Murali - Department of Gastroenterology, St. John's Medical College Hospital, Bangalore, India
Resource Type: Journal article
Publication Details: Journal of clinical and experimental hepatology, Vol.5(4), pp.310-313
DOI: 10.1016/j.jceh.2015.08.004
PMID: 26900272
PMCID: PMC4723655
ISSN: 0973-6883
eISSN: 2213-3453
Language: English
Date published: 12/2015
Academic Unit: Gastroenterology and Hepatology; Internal Medicine
Record Identifier: 9984094507002771

Metrics

9 Record Views

7 Times Cited - Web of Science